Nov. 18 at 5:17 PM
$MAJI
$MAJI $LMMY
Summary of Benefits to MAJI Shareholders from Nov 17, 2025 PR:
No dilution: Exousia AI can raise capital separately via LMMY (51% owned by MAJI) without diluting MAJI shareholders.
Retain upside: MAJI keeps ~51% of LMMY, giving shareholders continued exposure to Exousia AI’s high-growth AI-exosome potential.
Cleaner focus: MAJI sheds the old “Marijuana Inc.” stigma, improving talent/investor appeal and positioning it as a pure-play exosome biotech.
Risk separation: High-burn AI assets are ring-fenced; MAJI focuses on core clinical-stage exosome pipeline.
Enhanced value: Cleaner structure + non-dilutive growth path = stronger long-term shareholder value.
Result: Shareholders get the best of both worlds (core biotech + AI upside) with less dilution and better optics.
